-
MediWound (MDWD) Misses Q2 EPS by 66c
-
MediWound publishes phase II data linking wound preparation to healing
-
Oppenheimer Assumes MediWound Ltd (MDWD) at Outperform (correction)
-
MediWound Ltd (MDWD) PT Raised to $31 at H.C. Wainwright
-
MediWound (MDWD) Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
-
MediWound (MDWD) Tops Q4 EPS by 20c
-
Craig-Hallum Starts MediWound Ltd (MDWD) at Buy
-
MediWound (MDWD) Announces Phase III CIDS Publication on NexoBrid for Pediatric Burn Care
-
MediWound (MDWD) Initiates the VALUE Global Phase III Trial of EscharEx
-
MediWound (MDWD) Misses Q3 EPS by 53c
-
H.C. Wainwright Reiterates Buy Rating on MediWound Ltd (MDWD)
-
MediWound (MDWD) Announces Phase II Head-to-Head Study of EscharEx vs. Collagenase in Patients with Venous Leg Ulcers
-
TD Cowen Reiterates Buy Rating on MediWound Ltd (MDWD)
-
MediWound (MDWD) Announces FDA Approval of NexoBrid
-
TD Cowen Reiterates Buy Rating on MediWound Ltd (MDWD)
-
MediWound (MDWD) Misses Q2 EPS by 24c
-
TD Cowen Reiterates Buy Rating on MediWound Ltd (MDWD)
-
MediWound (MDWD) Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol
-
MediWound (MDWD) Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
-
TD Cowen Reiterates Buy Rating on MediWound Ltd (MDWD)
-
MediWound (MDWD) Announces EUR 16.25M Funding from the European Innovation Council Accelerator Program
-
MediWound enters PIPE deal, not takeover; sending shares sharply lower
-
MediWound (MDWD) Announces $25 Million Strategic Private Placement Financing
-
BTIG Reiterates Buy Rating on Vericel Corporation (VCEL)
-
MediWound (MDWD) spokesperson won't comment on takeover "rumors"
-
MediWound (MDWD) gains on report of takeover offer at large premium

